Allakos Reports Fourth Quarter and Full Year 2023 Financial Results
Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages AK006 inhibited mast cell activation and reduced mast cell numbers...
“ Data provide insights on the signaling pathways involved with AK006 mast cell inhibition ““ AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells “ SAN...
Allakos halves workforce, drops lead inflammatory program
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the œCompany) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the œCompany) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on...
“ AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib ““ AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated...